Lucanthone

Lucanthone

SCHEMBL9156

CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 7/20 1.00
MAPT P10636 6/20 1.00
CHRM2 P08172 2/20 1.00
HTR1A P08908 2/20 1.00
ADRA2A P08913 2/20 1.00
CHRM1 P11229 2/20 1.00
TBXA2R P21731 2/20 1.00
SLC6A2 P23975 2/20 1.00
APEX1 P27695 2/20 1.00
SLC6A4 P31645 2/20 1.00
ADRA1A P35348 2/20 1.00
OPRM1 P35372 2/20 1.00
DRD3 P35462 2/20 1.00
SLC6A3 Q01959 2/20 1.00
KCNH2 Q12809 2/20 1.00
HRH3 Q9Y5N1 2/20 1.00
ADORA3 P0DMS8 1/20 1.00
MAOA P21397 1/20 1.00
DRD1 P21728 1/20 1.00
RAD52 P43351 3/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lucanthone SCHEMBL29422254 1.00 APP (1.00) APPMAPTCHRM2HTR1AADRA2A
Lucanthone SCHEMBL30572937 1.00 APP (1.00) APPMAPTCHRM2HTR1AADRA2A
Lucanthone SCHEMBL29503548 0.99 APP (0.98) APPMAPTCHRM2HTR1AADRA2A
Lucanthone SCHEMBL419165 0.99 APP (0.98) APPMAPTCHRM2HTR1AADRA2A
Lucanthone SCHEMBL8004521 0.99 APP (0.98) APPMAPTCHRM2HTR1AADRA2A
Lucanthone SCHEMBL28172520 0.99 APP (0.98) APPMAPTCHRM2HTR1AADRA2A
Lucanthone SCHEMBL1650327 0.98 APP (0.96) APPMAPTCHRM2HTR1AADRA2A
Lucanthone SCHEMBL7517404 0.95 APP (0.90) APPMAPTCHRM2HTR1AADRA2A
SCHEMBL13856933 0.93 APP (0.86) APPMAPTCHRM2HTR1AADRA2A
Becanthone SCHEMBL1641785 0.91 APP (0.83) APPMAPTCHRM2HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 6097 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137806-A1 INTERCALATING SUGAR MOLECULES XALUD THERAPEUTICS, INC. (US) 2026-05-21 US claimed
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2026-03-26 US claimed
US-12577255-B2 MDM2-based modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-03-17 US claimed
EP-4704832-A2 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS Biohaven Therapeutics Ltd. (VG) 2026-03-11 EP claimed
US-20260022117-A1 COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS ARVINAS OPERATIONS INC (US) 2026-01-22 US claimed
US-12485178-B2 Bifunctional small molecules to target the selective degradation of circulating proteins YALE UNIVERSITY (US) 2025-12-02 US claimed
US-20250332274-A1 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS UNIV YALE (US) 2025-10-30 US claimed
US-20250295629-A1 COMPOSITIONS AND METHODS FOR TREATING CANCERS OF THE CENTRAL NERVOUS SYSTEM (CNS), INCLUDING GLIOBLASTOMA AND CHEMORESISTANT CNS TUMORS, AND RELATED COMPOSITIONS AND METHODS FOR INHIBITING AND ELIMINATING CNS CANCER STEM CELLS RADIN DANIEL PIERCE (US) 2025-09-25 US claimed
EP-4612132-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2025-09-10 EP claimed
EP-4586826-A1 FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL In the Bowl Animal Health, Inc. (US) 2025-07-23 EP claimed
WO-2000050031-A9 CO-ADMINISTRATION OF LUCANTHONE AND RADIATION FOR TREATMENT OF CANCER BASES ROBERT (US) 2002-06-20 WO claimed
US-6391911-B1 Coadministration of lucanthone and radiation for treatment of cancer BASES ROBERT E (US) 2002-05-21 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000050031-A1 CO-ADMINISTRATION OF LUCANTHONE AND RADIATION FOR TREATMENT OF CANCER BASES ROBERT (US) 2000-08-31 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0507629-B1 Sustained release capsule and formulations for insertion into rumen LILLY CO ELI (US) 1997-01-22 EP claimed
US-5277912-A Sustained release capsule and formulations ELI LILLY AND COMPANY (US) 1994-01-11 US claimed
CN-1067810-A Sustained-release capsule and preparation LILLY CO ELI (US) 1993-01-13 CN claimed
EP-0507629-A1 Sustained release capsule and formulations for insertion into rumen ELI LILLY AND COMPANY (US) 1992-10-07 EP claimed